Each filer's latest filing for 09090D103 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
James E. Flynn
13D/A
|
10.0% |
3/3/2025
Event 2/27/2025
|
||
| Deerfield Private Design Fund V, L.P. | 10.0% | |||
| Deerfield Mgmt V, L.P. | 10.0% | |||
| Deerfield Healthcare Innovations Fund II, L.P. | 10.0% | |||
| Deerfield Mgmt HIF II, L.P. | 10.0% | |||
| Deerfield Management Company, L.P. | 10.0% | |||
| James E. Flynn | 10.0% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
| Cystic Fibrosis Foundation 13G/A | 1.5% |
8/20/2026
Event 6/30/2026
|
||
|
OrbiMed Israel BioFund GP Limited Partnership
13D/A
|
1.0% |
6/23/2025
Event 6/18/2025
|
||
| Orbimed Israel GP Ltd. | 1.0% | |||
| Orbimed Israel Biofund GP Limited Partnership | 1.0% | |||
| Gordon Carl L | 1.0% | |||
| Chimovits Erez | 1.0% | |||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q3 | 2 | 97.0 k | $50.9k |
| 2025 Q2 | 2 | 97.0 k | $42.7k |
| 2025 Q1 | 2 | 97.0 k | $53.9k |
| 2024 Q4 | 1 | 96.9 k | $70.7k |
| 2024 Q3 | 2 | 301 k | $307k |
| 2024 Q2 | 13 | 23.2 M | $7.81M |
| 2024 Q1 | 11 | 13.8 M | $6.20M |
| 2023 Q4 | 15 | 8.09 M | $2.26M |
| 2023 Q3 | 12 | 7.45 M | $2.62M |
| 2023 Q2 | 12 | 7.71 M | $2.77M |
| 2023 Q1 | 15 | 6.33 M | $1.93M |
| 2022 Q4 | 16 | 6.16 M | $1.15M |
| 2022 Q3 | 17 | 6.16 M | $2.10M |
| 2022 Q2 | 13 | 6.18 M | $4.51M |
| 2022 Q1 | 15 | 6.62 M | $12.8M |
| 2021 Q4 | 16 | 6.57 M | $10.5M |
| 2021 Q3 | 19 | 6.95 M | $21.3M |
| 2021 Q2 | 15 | 6.09 M | $33.3M |
| 2021 Q1 | 15 | 6.18 M | $44.0M |
| 2020 Q4 | 11 | 6.28 M | $40.0M |
| 2020 Q3 | 11 | 6.22 M | $39.5M |
| 2020 Q2 | 14 | 6.12 M | $33.8M |
| 2020 Q1 | 12 | 6.04 M | $42.2M |
| 2019 Q4 | 9 | 5.16 M | $50.0M |
| 2019 Q3 | 1 | 100 k | $1.02M |